| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3396 |
| Trial ID | NCT05801939 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA CAR-T cells |
| Co-treatment | Cevostamab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
| Year | 2023 |
| Country | United States |
| Company sponsor | University of Pennsylvania |
| Other ID(s) | 853124, UPCC 02423 |
| Cohort 1 | |||||||||
|
|||||||||